Comparative Pharmacology
Head-to-head clinical analysis: EPKINLY versus IMDELLTRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPKINLY versus IMDELLTRA.
EPKINLY vs IMDELLTRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EPKINLY (epcoritamab-bysp) is a bispecific CD3xCD20 T-cell engager that binds to CD3 on T-cells and CD20 on B-cells, leading to T-cell-mediated lysis of CD20-expressing B-cells.
IMDELLTRA is a bispecific T-cell engager that binds to CD3 on T cells and delta-like ligand 3 (DLL3) on small cell lung cancer cells, leading to T-cell-mediated cytotoxicity.
Administered subcutaneously at a dose of 0.6 mg/kg (maximum 40 mg) initially, then 1 mg/kg (maximum 80 mg) on Day 8, then 2 mg/kg (maximum 160 mg) on Day 15, and 3 mg/kg (maximum 240 mg) on Day 22, followed by 3 mg/kg (maximum 240 mg) every 4 weeks thereafter.
1.5 mg subcutaneously once weekly.
None Documented
None Documented
The terminal elimination half-life is approximately 22 days (range 14–37 days), supporting a 4-week dosing interval for subcutaneous administration.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Epkinly (epcoritamab) is not metabolized by CYP enzymes; elimination is primarily via catabolism into small peptides and amino acids. No dedicated excretion studies have been conducted; based on its monoclonal antibody nature, renal and biliary excretion are minimal. The expected elimination pathways are proteolytic degradation throughout the body.
Renal elimination: 70% as unchanged drug; fecal elimination: 20% as metabolites; biliary excretion: 10% as parent and metabolites.
Category C
Category C
Bispecific Antibody
Bispecific Antibody